Variability of Two Metabolomic Platforms in CKD.

ABSTRACT:

Background and objectives

Nontargeted metabolomics can measure thousands of low-molecular-weight biochemicals, but important gaps limit its utility for biomarker discovery in CKD. These include the need to characterize technical and intraperson analyte variation, to pool data across platforms, and to outline analyte relationships with eGFR.

Design, setting, participants, & measurements

Plasma samples from 49 individuals with CKD (eGFR<60 ml/min per 1.73 m² and/or ≥1 g proteinuria) were examined from two study visits; 20 samples were repeated as blind replicates. To enable comparison across two nontargeted platforms, samples were profiled at Metabolon and the Broad Institute.

Results

The Metabolon platform reported 837 known metabolites and 483 unnamed compo

SUBMITTER: Rhee EP 

PROVIDER: S-EPMC6364529 | biostudies-literature | 2019 Jan

REPOSITORIES: biostudies-literature